Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups: FLOW Trial Post Hoc Analyses

BACKGROUND: Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups. METHODS: Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity. RESULTS: Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05). CONCLUSION: In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.

Authors

Institutions

Publication Details

Journal
Clinical Journal of the American Society of Nephrology
Published
2026-11-18
DOI
https://doi.org/10.2215/cjn.0000001242
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups: FLOW Trial Post Hoc Analyses

Christian W. Mende, Kenneth W. Mahaffey, SHERIF J. MEHANNA, Katherine R. Tuttle et al.
8 links
Clinical Journal of the American Society of Nephrology
Diabetes Treatment and Management
article

Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups: FLOW Trial Post Hoc Analyses

Christian W. Mende, Kenneth W. Mahaffey, SHERIF J. MEHANNA, Katherine R. Tuttle, Caroline Swift, Richard E. Pratley, Peter R Rossing, David M. Charytan, Robert S. Busch, Søren Rasmussen, Carlos Campos
article en

Abstract

BACKGROUND: Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups. METHODS: Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity. RESULTS: Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05). CONCLUSION: In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.

Clinical Journal of the American Society of Nephrology
Novo Nordisk (Denmark) (DK), University of Washington (US), AdventHealth Orlando (US), Inland Northwest Health Services (US), University of California San Diego (US), Diabetes Care Center (US), Stanford Medicine (US), Steno Diabetes Center Copenhagen (DK), Albany Med Health System (US), AdventHealth (US), New York University (US), Stanford University (US)
Good health and well-being, Reduced inequalities
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon